Etirinotecan pegol - JenKem Technology

Drug Profile

Etirinotecan pegol - JenKem Technology

Alternative Names: JK-1201l; PEG-irinotecan - JenKem; Pegylated irinotecan - 3SBio; Pegylated irinotecan - JenKem; SSS 22

Latest Information Update: 19 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator JenKem Technology
  • Developer 3SBio; JenKem Technology
  • Class Alkaloids; Antineoplastics; Camptothecins; Heterocyclic compounds with 4 or more rings; Indolizines; Piperidines; Polyethylene glycols; Quinolines
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 19 Sep 2016 Phase-I clinical trials in Solid tumours in China (Parenteral) before September 2016 (3SBio pipeline, September 2016)
  • 09 Mar 2016 The China Food and Drug Administration approves IND application for etirinotecan pegol in Solid tumours
  • 16 Sep 2014 Etirinotecan pegol licensed to 3SBio in China
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top